Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025
Download Free Sample Buy Now
Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2025

Report Price : $4490.00

Pages : 175

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025

By Drug Class (Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

• Vasomotor Menopausal Symptoms (VMS) Treatment market size has reached to $17.86 billion in 2024

• Expected to grow to $24.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%

• Growth Driver: Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market

• Market Trend: Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options

• North America was the largest region in 2024.

What Is Covered Under Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

The main types of drugs in vasomotor menopausal symptoms (VMS) treatment are antidepressants, fluoxetine, paroxetine, sertraline, hormone therapy, anticonvulsants, phenytoin, phenobarbital and others. Antidepressants refer to a class of medications primarily used to treat depression and certain other mental health disorders. They are distributed in several ways, such as in hospital pharmacies, online pharmacies, retail pharmacies and others for various end-users such as hospitals, specialty clinics, homecare and others.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and growth rate 2025 to 2029: Graph

What Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Size 2025 And Growth Rate?

The vasomotor menopausal symptoms (VMS) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.

What Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Forecast?

The vasomotor menopausal symptoms (VMS) treatment market size is expected to see strong growth in the next few years. It will grow to $24.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).

The forecast of 6.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. menopausal care by inflating prices of non-hormonal neurokinin-3 antagonists and cooled radiofrequency devices developed in Denmark and Japan, resulting in prolonged symptom suffering and higher gynecology specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmented?

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

What Is Driving The Vasomotor Menopausal Symptoms (VMS) Treatment Market? Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market

The increase in the menopause population is expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Menopause is a natural biological process that marks the end of a woman's reproductive years. It is a significant life stage that typically occurs in women between the ages of 45 and 55, with the average age being around 51. The rising number of menopausal women, which demands treatment for hot flashes and vaginal dryness globally, is one of the primary factors pushing the growth of vasomotor menopausal symptoms (VMS) treatment. For instance, in November 2022, according to the Cuyuna Regional Medical Center, a US-based organization, estimated that by 2025, 1.1 billion women will be menopausal due to women living longer. Moreover, the population of menopausal will be increased by 1.6% annually until 2060. Therefore, the increase in the menopause population is driving the growth of the vasomotor menopausal symptom’s treatment market.

What Is Driving The Vasomotor Menopausal Symptoms (VMS) Treatment Market? Government Women's Health Initiatives Boost Vasomotor Menopausal Symptom Treatment Market

The government's initiatives for women's health in menopause are expected to propel the growth of the vasomotor menopausal symptom’s treatment market going forward. Government initiatives for menopausal health encompass funding for innovative studies on menopausal transition, illness prevention, and research related pharmacological, clinical, and epidemiological aspects. These efforts are part of broader women's health initiatives that address diverse concerns. For instance, in January 2023, according to the Government of New South Wales, an Australia-based government agency, the government initiated $40.3 million over four years (2022-2023 to 2025-2026) to build up to 16 new programs for women facing severe menopausal symptoms. Therefore, the government's initiatives for women's health in menopause are driving the growth of the vasomotor menopausal symptoms’ treatment market.

Who Are The Major Players In The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Major companies operating in the vasomotor menopausal symptoms (VMS) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

What Are The Key Trends Of The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market? Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options

Major companies operating in the vasomotor menopausal symptoms treatment market are developing products such as Veozah and getting approvals to provide new treatment options and meet unmet medical needs for patients. The approval of new drugs for menopause provides improved efficacy and safety compared to existing treatments. For instance, in May 2023, Astellas Pharma Inc, a Japan-based pharmaceutical company, received approval for Veozah (fezolinetant) 45 mg once daily from the Food and Drug Administration (FDA), a US-based federal agency for the treatment of menopausal vasomotor symptoms (VMS), which range from mild to severe. It is the first nonhormonal neurokinin 3 (NK3) receptor antagonist to be authorized for treating menopausal-related VMS. It is a hormone-free option that blocks a pathway in the brain that helps regulate these symptoms. It provides an alternative treatment option for women experiencing these symptoms, particularly those who cannot or prefer not to use hormone therapy. The approval of Veozah highlights its potential as a new drug for managing menopausal symptoms.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market? Amyris Inc. Expands Women's Health Portfolio With Acquisition Of Menolabs Llc

In March 2022, Amyris Inc., a US-based biotechnology company, acquired MenoLabs LLC for $35.4 million. With this acquisition, Amyris aims to expand its women's health market presence, gain access to new technologies and capabilities and acquire a loyal customer base. MenoLabs LLC is a US-based women's health and technology company that develops dietary supplements to treat women's menopause symptoms.

Regional Outlook For The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?

The vasomotor menopausal symptoms (vms) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vasomotor menopausal symptoms (vms) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $19.01 billion
Revenue Forecast In 2034 $24.5 billion
Growth Rate CAGR of 6.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT) 6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives 7) Phenytoin: Hydantoins 8) Phenobarbital: Barbiturates 9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical plc, Endo Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics

3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies

4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Growth Rate Analysis

5.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Total Addressable Market (TAM)

6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation

6.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antidepressants

Fluoxetine

Paroxetine

Sertraline

Hormone Therapy

Anticonvulsant

Phenytoin

Phenobarbital

Other Drug Classes

6.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Other Distribution Channels

6.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End-Users

6.4. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

SSRIs (Selective Serotonin Reuptake Inhibitors)

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

TCAs (Tricyclic Antidepressants)

MAOIs (Monoamine Oxidase Inhibitors)

Atypical Antidepressants

6.5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depression

Obsessive-Compulsive Disorder (OCD)

Panic Disorder

Generalized Anxiety Disorder (GAD)

Post-Traumatic Stress Disorder (PTSD)

Social Anxiety Disorder

Premenstrual Dysphoric Disorder (PMDD)

6.6. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depression

Obsessive-Compulsive Disorder (OCD)

Panic Disorder

Generalized Anxiety Disorder (GAD)

Post-Traumatic Stress Disorder (PTSD)

Social Anxiety Disorder

Premenstrual Dysphoric Disorder (PMDD)

6.7. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depression

Obsessive-Compulsive Disorder (OCD)

Panic Disorder

Post-Traumatic Stress Disorder (PTSD)

Social Anxiety Disorder

Premenstrual Dysphoric Disorder (PMDD)

6.8. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Estrogen Replacement Therapy (ERT)

Progestin Therapy

Combined Hormonal Therapy (CHT)

Testosterone Replacement Therapy (TRT)

6.9. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hydantoins

Barbiturates

Benzodiazepines

Valproates

Succinimides

Carboxylic Acid Derivatives

6.10. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hydantoins

6.11. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Barbiturates

6.12. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antibiotics

Analgesics

Antidiabetics

Antihypertensives

Anticoagulants

Immunosuppressants

Antipsychotics

Antihistamines'

7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis

7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market

8.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market

9.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

9.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market

10.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market

11.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

11.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market

12.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market

13.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market

14.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

14.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

15.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

15.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market

16.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market

17.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market

18.1. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market

19.1. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market

20.1. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market

21.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

21.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market

22.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market

23.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

23.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market

24.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

24.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market

25.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

25.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market

26.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

26.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market

27.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market

28.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

28.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market

29.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview

29.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles

30.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape

30.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Ausio Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies

31.1. Mylan N.V.

31.2. Sun Pharmaceutical Industries Ltd.

31.3. Aurobindo Pharma Limited

31.4. Kyowa Kirin Co. Ltd.

31.5. Dr. Reddy's Laboratories Ltd.

31.6. Alembic Pharmaceuticals Limited Inc.

31.7. Apotex Inc.

31.8. Hikma Pharmaceutical plc

31.9. Endo Pharmaceuticals plc

31.10. Amneal Pharmaceuticals LLC

31.11. Mundipharma International Ltd.

31.12. Lupin Limited

31.13. Glenmark Pharmaceuticals Ltd.

31.14. Hisamitsu Pharmaceutical Co. Inc.

31.15. Zhejiang Huahai Pharmaceutical Co. Ltd.

32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

34. Recent Developments In The Vasomotor Menopausal Symptoms (VMS) Treatment Market

35. Vasomotor Menopausal Symptoms (VMS) Treatment Market High Potential Countries, Segments and Strategies

35.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Countries Offering Most New Opportunities

35.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Segments Offering Most New Opportunities

35.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 82: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 83: Pfizer Inc. Financial Performance
  • Table 84: Abbvie Inc. Financial Performance
  • Table 85: Novartis AG Financial Performance
  • Table 86: Ausio Pharmaceuticals LLC Financial Performance
  • Table 87: Teva Pharmaceutical Industries Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Fluoxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Paroxetine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Sertraline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Anticonvulsant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenytoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Phenobarbital, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Asia-Pacific, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: China, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: India, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Japan, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Australia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Indonesia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: South Korea, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Western Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: UK, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Germany, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: France, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Italy, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Spain, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Eastern Europe, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Russia, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: North America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: USA, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Canada, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: South America, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Brazil, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Middle East, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 82: Africa, Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 83: Pfizer Inc. Financial Performance
  • Figure 84: Abbvie Inc. Financial Performance
  • Figure 85: Novartis AG Financial Performance
  • Figure 86: Ausio Pharmaceuticals LLC Financial Performance
  • Figure 87: Teva Pharmaceutical Industries Ltd. Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Read More About Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Read More About Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Read More About Explore the latest trends, growth insights, and forecasts in the Key Trend Shaping The Ophthalmology Medical Service Market.

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025 – By Drug Class (Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes)...

View Report

Menopausal Hot Flashes Global Market Report 2025 – By Type (Hormonal Treatment, Non-hormonal Treatment, Alternative Treatment), By Pipeline Analysis (Phase III Drugs, Phase I and II Drugs), By Distribution Channel (Retai...

View Report

Menopause Global Market Report 2025 – By Treatment (Dietary Supplements, Over-The-Counter (OTC) Pharma Products), By Route of Administration (Topical, Oral, Injectables), By Distribution Channel (Hospital, Retail, Online...

View Report

Vulvodynia Treatment Global Market Report 2025 – By Drug Type (Anticonvulsants, Tricyclic Antidepressants, Local Anesthetics, Antimicrobials, Hormone Creams, Nerve Blocks, Other Drug Types), By Route of Administration (O...

View Report

Vaginitis Therapeutics Global Market Report 2025 – By Drug Type (Nitroimidazole Compound, Lincosamide Antibiotics, Triazoles, Imidazoles), By Route Of Administration (Oral, Cutaneous, Vaginal), By Indication Type (Bacter...

View Report

Vaginal Rejuvenation Global Market Report 2025 – By Type (Surgical, Non-Surgical), By Treatment Type (Reconstructive Vaginal Rejuvenation, Cosmetic Vaginal Rejuvenation), By Application (Incontinence, Aesthetic Purposes,...

View Report

Vitiligo Treatment Global Market Report 2025 – By Drugs (Antihistamines, H2 Antagonists, Tricyclic Antidepressants, Other Drugs), By Types (Acute Urticaria, Chronic Urticaria), By Mode Of Administration (Injectable, Oral...

View Report

Virology Testing Global Market Report 2025 – By Type (Instruments, Assay Kits And Consumables), By Diagnostic Technique (Molecular Diagnostics Method, Immunoassay Based Method, Mass Spectroscopy Based Method, Other Techn...

View Report

Frequently Asked Questions

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain. For further insights on this market, request a sample here

The market major growth driver - Menopausal Population Growth Fuels Expansion Of Vasomotor Menopausal Symptoms Treatment Market. For further insights on this market, request a sample here

The vasomotor menopausal symptoms (vms) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.01 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand. The vasomotor menopausal symptoms (vms) treatment market size is expected to see strong growth in the next few years. It will grow to " $24.5 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt). For further insights on this market, request a sample here

The vasomotor menopausal symptoms (vms) treatmentmarket covered in this report is segmented –
1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors); TCAs (Tricyclic Antidepressants); MAOIs (Monoamine Oxidase Inhibitors); Atypical Antidepressants
2) By Fluoxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT); Progestin Therapy; Combined Hormonal Therapy (CHT); Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins; Barbiturates; Benzodiazepines; Valproates; Succinimides; Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics; Analgesics; Antidiabetics; Antihypertensives; Anticoagulants; Immunosuppressants; Antipsychotics; Antihistamines For further insights on this market, request a sample here

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on this market, request a sample here.

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.. For further insights on this market, request a sample here.

Major trends in this market include Increasing The Emphasis On Drug Approvals To Provide Better Treatment Options. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon